

January 31, 2014

GlyTech Secures 600 Million JPY in Series A Financing From Japanese Leading Venture Capital Firms

GlyTech Inc. (Kyoto, Japan), a world leading company of glycosylation, today announced that it has raised 600 million JPY in a Series A financing from four venture capital firms, the University of Tokyo Edge Capital Co. Ltd. (UTEK), DBJ Capital Co., Ltd., Mitsui Sumitomo Insurance Venture Capital and Mitsubishi UFJ Capital Co. Ltd.

GlyTech was founded in April 2012 as a fully-owned subsidiary of Otsuka Chemical Co., Ltd and then became independent from Otsuka Chemical through a management buyout in 2013 with purpose of commercializing the glycosylation technology developed by Professor Yasuhiro Kajihara at Osaka University. GlyTech is a world leader in glycoscience/glycotechnology, having established the large-scale manufacturing process for highly purified and characterized human type N-glycans as well as the chemical synthesis of glycosylated compounds, especially glycopeptides and glycoproteins. GlyTech's technologies can contribute to developing better and lower-cost biopharmaceuticals and has just launched several partnership services. GlyTech expects to play a significant role in developing bio-betters and innovative biopharmaceutical products.

GlyTech has entered into several alliances with other companies including domestic and international companies. For example, their collaboration with Bachem Holding AG in Switzerland, a world leading company in the custom manufacture of peptides, has resulted in successfully developing the scalable manufacturing processes of chemically synthetic Interferon β -1a.

GlyTech plans to use the capital to not only improve the company's organizational structure and facilitate R&D activities but also to support its rapidly expanding business opportunities using its innovative platform.

About GlyTech

Company Name: GlyTech, Inc.

Headquarters: 134, Chudoji Minamimachi, Shimogyo-ku, Kyoto 600-8813, Japan

Representative: Hiroaki ASAI, CEO

Motto: GlyTech aims to create and provide the novel chemically synthetic technology through Nature Mimetic Technology.

Business Activities: Contract research of biopharmaceuticals; manufacturing, sales, import and export of bulk drugs

Capital: 458 million JPY (after capital increase)

Founded: April 2012

About The University of Tokyo Edge Capital Co. Ltd. (UTECE)

Headquarters: Bunkyo-ku, Tokyo

Representative: Tomotaka GOJI, Managing Partner

<http://www.ut-ec.co.jp/>

About DBJ Capital Co., Ltd.

Headquarters: Chiyoda-ku Tokyo

Representative: Fumiya KASHIMA, President and CEO

<http://www.dbj-cap.jp/>

About Mitsui Sumitomo Insurance Venture Capital

Headquarters: Chuo-ku, Tokyo

Representative: Hitoshi IGARASHI, President

http://www.msivc.co.jp/top_en.html

About Mitsubishi UFJ Capital Co. Ltd

Headquarters: Chuo-ku, Tokyo,

Representative: Kei ANDOH, President

<http://www.mucap.co.jp/>

For More Information:

Business Development Division Senior Investigator: Naoki Yamamoto, Ph.D.

E-mail: glytech-info@glytech.jp Tel: +81-75-315-9218 Fax: +81-75-315-9225

Website: <http://www.glytech.jp> (English/Japanese)

Inquiry Form: http://www.glytech.jp/en/glyt_en.html

End of Press Release